RNA复兴:利用非编码RNA疗法来治疗肝细胞癌
Subhas Das1, Soumyabrata Chatterjee1, Tushar Patel2
1Centre for Liver Research, School of Digestive and Liver Diseases, Institute of Post Graduate Medical Education and Research, Kolkata, India.
Pharmacology & therapeutics
|November 14, 2025
概括
非编码RNAs (ncRNAs),包括microRNAs (miRNAs) 和长非编码RNAs (lncRNAs),是肝癌中涉及的基因表达的关键调节者. 准这些ncRNAs为肝细胞癌 (HCC) 提供了一个有前途的治疗策略.
科学领域:
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
- 在瘤学瘤学.
背景情况:
- 非编码RNAs (ncRNAs) 在转录和转化层面调节基因表达.
- ncRNAs,特别是microRNAs (miRNAs),循环RNAs (circRNAs) 和长非编码RNAs (lncRNAs) 的失调与包括癌症在内的各种疾病有关.
- 由于ncRNAs能够调节多个基因和途径,因此提供了多方面的治疗方法.
研究的目的:
- 在肝细胞癌 (HCC) 中对放松调节的miRNA进行元分析.
- 为了确定多功能miRNAs驱动HCC中的瘤性途径.
- 探索长非编码RNAs (lncRNAs) 作为治疗点,通过对HCC.中的miRNAs进行隔离.
主要方法:
- 对在HCC中放松调节的miRNA发表文献的元分析.
- 在HCC中分离miRNAs的lncRNAs的鉴定.
- 对已识别的miRNAs和lncRNAs进行实验验证的审查.
主要成果:
- 在HCC中鉴定出调节后的miRNA,驱动各种致癌途径.
- 突出显示 lncRNAs 作为 HCC 中有前途的治疗点,因为它们在隔离 miRNAs 中的作用.
- 证实了基于ncRNA治疗肝癌的潜力,利用肝脏的吸收能力.
结论:
- ncRNAs,特别是miRNAs和lncRNAs,是HCC病原和进展中的重要参与者.
- 针对特定的ncRNAs是HCC的可行治疗策略.
- 尽管临床前数据充满希望,但在将基于ncRNA的治疗方法转化为HCC的临床试验方面仍然存在挑战.
相关概念视频
Experimental RNAi
7.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.2K
Types of RNA
9.0K
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
RNA Performs Diverse...
9.0K
lncRNA - Long Non-coding RNAs
9.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
lncRNA - Long Non-coding RNAs
3.5K
3.5K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
RNA Interference
27.7K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
27.7K


